-
1.发明授权公开(公告)号：US09605046B2
公开(公告)日：2017-03-28
申请号：US14356692
申请日：2012-11-07
IPC分类号： A61K38/00 , A61P5/00 , C07K14/705 , A61K38/17
CPC分类号： C07K14/705 , A61K38/00 , A61K38/177
摘要： The present invention provides novel PAR 1 derived cytoprotective oligopeptides or polypeptides which typically contain at least the first 4 N-terminal residues that are substantially identical to the corresponding N-terminal residues of Met1-Arg46 deleted human PAR 1 sequence. These cytoprotective oligopeptides or polypeptides are capable of activating PAR 1 and promoting PAR 1 cytoprotective signaling activities. The invention also provides engineered cells or transgenic non-human animals which harbor in their genome an altered PAR 1 gene that is resistant to cleavage at Arg41 and/or Arg46 residues. Additionally provided in the invention are methods of screening candidate compounds to identity additional cytoprotective compounds or cytoprotective proteases. The invention further provides therapeutic use or methods of employing a PAR 1 derived cytoprotective oligopeptide or polypeptide to treat conditions associated with tissue injuries or undesired apoptosis.
-
公开(公告)号：US20220313780A1
公开(公告)日：2022-10-06
申请号：US17617989
申请日：2020-06-17
摘要： The present invention provides novel compositions for suppressing inflammation and for treating inflammatory disorders. These compositions contain at least one PARS-derived anti-inflammatory peptide or polypeptide and/or at least one PARI-derived anti-inflammatory peptide or polypeptide. The PARS- and/or PARI-derived peptides typically contain an amino acid sequence that mimics the respective N-terminal sequence of Activated Protein C-cleaved PARS or PARI, e.g., after activated protein C cleavage at residue Arg41 in human PARS and after residue Arg46 in human PARI. The invention also provides therapeutic methods of using the anti-inflammatory compositions described herein to suppress undesired inflammation and to treat inflammatory disorders. Additionally provided in the invention are methods of screening candidate compounds to identity novel anti-inflammatory agents.
-
公开(公告)号：US20200054721A1
公开(公告)日：2020-02-20
申请号：US16343640
申请日：2017-10-20
申请人： Bruce R. BLAZAR , John H. GRIFFIN , Ryan P. FLYNN , Ranjeet K. SINHA , Regents of the University of Minnesota , The Scripps Research Institute
摘要： This disclosure provides materials and methods for treating or preventing graft-versus-host-disease (GVHD) using protein C or activated protein C or a signaling-selective variant or mutant thereof.
-
公开(公告)号：US20220340629A1
公开(公告)日：2022-10-27
申请号：US17824186
申请日：2022-05-25
发明人： John H. Griffin , Hiroshi Deguchi , Weijun Shen , Sam Lear , Elsa Pflimlin , Yvonne Marie Angell , Mike Lizarzaburu
摘要： The present invention provides myosin derived peptides, variants and derivative compounds that are anti-coagulant. Also provided in the invention are antibodies that specifically target the peptides or epitopes presented thereon. Further provided in the invention are methods directed to using the anti-coagulant compounds described herein in therapeutic applications, e.g., inhibiting myosin-supported prothrombin activation to reduce the risk of acute trauma coagulopathy in post-trauma patients or inhibiting cardiac myosin-supported prothrombin activation to reduce the risk of coronary thrombosis.
-
5.发明授权公开(公告)号：US10407488B2
公开(公告)日：2019-09-10
申请号：US15034385
申请日：2014-11-04
IPC分类号： A61K38/36 , C07K14/745 , A61K38/48 , A61K45/06
摘要： The present application generally relates to methods to prevent or treat bleeding and/or hypocoagulation in an individual in need thereof, and compositions for use in such methods. The methods comprise administration of FVa, preferably an APC resistant FVa (such as superFVa), alone or in combination with FVIIa, preferably rhFVIIa (such as NovoSeven® or another FVIIa having enhanced activity or half-life). When administered in combination, FVa and FVIIa elicit a synergistic benefit when used to treat or prevent bleeding or hypocoagulation in subjects in need thereof, e.g., subjects with a genetic disorder such as hemophilia or an acquired bleeding disorder or other condition associated with bleeding or hypocoagulation such as hemorrhagic stroke or shock, trauma, surgery or dysmenorrhea or individuals who produce inhibitory antibodies against procoagulants such as FVIII or FIX or who have been administered an overdose of an anticoagulant drug such as a direct Xa or direct thrombin inhibitor or a Novel Oral Anti-Coagulant (NOAC) or demonstrate unexplained bleeding. Also, the invention relates to the use of a superFVa alone or in combination with FVIIa or other procoagulant or prohemostatic agent to prevent, treat or reverse APC-associated bleeding, e.g., as the result of APC overproduction (such as through serious injury and/or hemorrhagic shock) or APC or other anticoagulant therapy, e.g., in the treatment of inflammatory disorders or sepsis disease.
-
6.发明授权公开(公告)号：US10273279B2
公开(公告)日：2019-04-30
申请号：US15470117
申请日：2017-03-27
IPC分类号： A61K38/00 , A61K38/17 , C07K14/705
摘要： The present invention provides novel PAR1 derived cytoprotective oligopeptides or polypeptides which typically contain at least the first 4 N-terminal residues that are substantially identical to the corresponding N-terminal residues of Met1-Arg46 deleted human PAR1 sequence. These cytoprotective oligopeptides or polypeptides are capable of activating PAR1 and promoting PAR1 cytoprotective signaling activities. The invention also provides engineered cells or transgenic non-human animals which harbor in their genome an altered PAR1 gene that is resistant to cleavage at Arg41 and/or Arg46 residues. Additionally provided in the invention are methods of screening candidate compounds to identity additional cytoprotective compounds or cytoprotective proteases. The invention further provides therapeutic use or methods of employing a PAR1 derived cytoprotective oligopeptide or polypeptide to treat conditions associated with tissue injuries or undesired apoptosis.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.018 秒)